A Transtheoretical Model Group Therapy for Cocaine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00178776
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 11, 2017
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
, National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to determine the feasibility and promise of a recently manualized group therapy based on the Transtheoretical Model for cocaine use disorders.

Condition or disease Intervention/treatment Phase
Cocaine Use Disorders Behavioral: Transtheoretical Model Group Therapy Behavioral: Education & Advice Phase 1

Detailed Description:
Cocaine use in the general population is a significant and costly problem. Novel and innovative interventions targeting cocaine abuse are needed. The Transtheoretical Model of behavior change (TTM) offers a comprehensive framework for understanding, measuring, and intervening in behavior change and provides a strong theoretical foundation upon which effective treatments for substance abuse can be developed. The proposed Stage 1 research will pilot test a novel and innovative behavioral group therapy for cocaine users based on the TTM. In Phase 1, investigators will modify the newly developed Group Treatment for Substance Abuse: A Stages-of-Change Therapy Manual (Velasquez, Maurer, Crouch & DiClemente, 2001) to specifically target cocaine abuse resulting in a twelve-session, group intervention and accompanying therapy manual based on the TTM stages and processes of change: six "early stage" sessions targeting the experiential processes of change, and six "later stage" sessions targeting the behavioral processes of change. Phase 2 will consist of a pilot trial to evaluate the TTM group therapy with cocaine abusing patients. A randomized, controlled, between groups design will be used in which cocaine abusers (N=80) are assigned to one of two group treatment conditions: TTM therapy or Education/Advice. Participants will be recruited from Houston and surrounding communities through the Substance Abuse Research Center at the University of Texas Health Science Center Mental Sciences Institute. We expect the delivery of the TTM therapy for cocaine users to be feasible and acceptable, and to produce significant patient improvement. Cocaine outcomes will be assessed via objective (urine and drug analysis) and self-report measures. This Stage I research will contribute important theoretical and empirical information concerning the promise of a new and innovative intervention for cocaine abusers, and will provide the basis for a larger efficacy trial.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 138 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Transtheoretical Model Group Therapy for Cocaine
Study Start Date : October 2003
Actual Primary Completion Date : November 2006
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Transtheoretical Model Group Behavioral: Transtheoretical Model Group Therapy
Active Comparator: Education / Advice Behavioral: Education & Advice

Primary Outcome Measures :
  1. Urinalysis indicating presence or absence of cocaine metabolites, used to calculate percent days abstinent, collected at intake, once weekly during the 6 week group treatment phase, at post-treatment, and 3 months.

Secondary Outcome Measures :
  1. Secondary Outcome Measures Related to Cocaine and other Drug Use:
  2. 1) Timeline Follow-Back (self-reported use / percent days
  3. abstinent)
  4. 2) Cocaine Craving Worksheet (self report)
  5. 3) Cocaine Negative Consequences Checklist (self report)
  6. 4) Addiction Severity Index (ASI; Interviewer Administered)
  7. 5) Blood Alcohol Breath (biological)
  8. 6) Substance Use Report (self report)
  9. Secondary Outcome Measures Related to Feasibility of the Group Therapy:
  10. 1) Participation / Attendance / Retention
  11. 2) MI Scale (Therapist Adherence)
  12. 3) Treatment Satisfaction Questionnaire
  13. 4) Group Therapy Alliance Scale
  14. 5) Group Atmosphere Scale
  15. 6) Therapist Treatment Evaluation
  16. Secondary Outcome Measures Related to Psychiatric Symptoms:
  17. 1) Beck Depression Inventory (BDI-II)
  18. 2) Brief Symptom Inventory (BSI)
  19. Secondary Outcomes Related to Functioning:
  20. 1) HIV Knowledge Questionnaire
  21. 2) Risk Behavior Assessment
  22. 3) SF-12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Inclusion Criteria: Male and female adults (ages 18-65 years old), of any race, who meet DSM-IV criteria for cocaine abuse or dependence disorder will be recruited. In addition, eligible participants must be:

  • (1) judged to be in generally good physical and psychiatric health except for possible acute drug related problems;
  • (2) willing and able to participate in the 6-week, group outpatient treatment;
  • (3) able to provide the name of at least one person who can generally locate their whereabouts; and
  • (4) willing to be followed for 3 months after treatment ends.

Potential subjects with simple drug charges whose legal contacts are willing to forego data revelation will be included. Although cocaine dependence will be the primary drug for which patients are seeking treatment, we will not exclude participants who are abusing additional substances.

Exclusion Criteria:

Individuals will be ineligible for study participation based on the following criteria:

  • (1) current diagnosis of an Axis I psychiatric disorder other than cocaine dependence;
  • (2) current psychiatric symptoms requiring medication;
  • (3) severe medical, cognitive and /or psychiatric impairment that precludes cooperation with study protocol;
  • (4) substance withdrawal symptoms requiring medical attention;
  • (5) currently receiving other psychosocial therapy for substance abuse with the exception of AA, NA or CA;
  • (6) impending incarceration;
  • (7) inability to read, write, speak English;
  • (8) inability or unwillingness to participate in the 6-week, group outpatient treatment (e.g., halfway house or other aftercare program restrictions).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00178776

United States, Texas
University of Texas Houston Mental Sciences Institute
Houston, Texas, United States, 77030
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
The University of Texas Health Science Center, Houston
Principal Investigator: Mary Marden Velasquez, Ph.D. University of Texas Houston Medical School, Dept. of Family & Community Medicine

Velasquez, M. M., Maurer, G. G., Crouch, C., & DiClemente, C. C. (2001). Group treatment for substance abuse: A stages-of-change therapy manual. New York: Guilford Press.

Responsible Party: , Professor, National Institute on Drug Abuse (NIDA) Identifier: NCT00178776     History of Changes
Other Study ID Numbers: 5R01DA015453-02 ( U.S. NIH Grant/Contract )
R01DA015453-02 ( U.S. NIH Grant/Contract )
UT CPHS ID - HSC-MS-02-138 ( Other Identifier: University of Texas Health Science Center Houston )
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: September 2014

Keywords provided by , National Institute on Drug Abuse (NIDA):

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents